Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
For the latest in critical pharmaceutical industry news, tap into a vast store of timely articles from Pharma Intelligence. With depth and breadth of coverage unparalleled in the industry, our articles span every aspect of medical and pharmaceutical news, covering all facets of pharma today. Whatever topic is most critical to you, you’ll find expert coverage of current pharmaceutical news from our dedicated teams of experts stationed around the globe.
100+ Total results for product and free and sample content found
Pink Sheet
By Sue Sutter 13 Oct 2021
Immune responses to a single booster dose of mRNA-1273 would be considered successfully bridged to the two-dose primary series if each of two immunobridging criteria were met, but the mRNA vaccine missed the prespecified success criteria for seroresponse rate, the FDA said.
Medtech Insight
By Marion Webb 12 Oct 2021
In this roundup of developments in digital health, we highlight the key news and announcements from August and September.
Pink Sheet
By Francesca Bruce 12 Oct 2021
The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.
Medtech Insight
By Barnaby Pickering 12 Oct 2021
In a panel discussion at The Medtech Conference, hosted by AdvaMed, CEOs discussed the challenges, benefits and technicalities surrounding an IPO.
HBW Insight
By Ryan Nelson 08 Oct 2021
At NAD 2021, Adam Waheed, an award-winning content creator with more than 17m social media followers, addressed challenges and legal risks that have escalated in recent years as influencer marketing opportunity exploded in the US and abroad.
Scrip
By Mandy Jackson 05 Oct 2021
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.
Scrip
By Ian Haydock 04 Oct 2021
In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.
Scrip
By Joseph Haas 01 Oct 2021
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
Scrip
28 Sep 2021
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
